Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... In a meaningful ... at Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this ... of its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and ... cutting-edge health care technology vendors, will take place May 14-17, 2016 in Minneapolis, ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Biz Report, which takes a look at small, medium, and large businesses making ... business expert, conducted the business review and shared with viewers how DevExpress has ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... its position as one of Medicare’s top-rated care centers. The video highlights ... CMS rating system, which monitors health inspections, staffing, and quality measures. Beachside ...
(Date:7/30/2015)... NJ (PRWEB) , ... July 30, 2015 , ... ... continues to expand, as the company and UCLA’s Jonsson Comprehensive Cancer Center ... OncLive announced today. With the new collaboration, OncLive’s editorial and marketing groups will ...
Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... new study shows that getting primary care physicians and ... an excellent way to extend the communication between doctors ... Medical School in London tested the "virtual outreach" method ... at an urban and rural health care facility. About ...
... a new research there has been a finding that, each ... diagnosed in the United States. Nearly 2,000 of these cases ... into a person's diet may reduce their risk of mouth ... cancers worldwide. Researchers have long known tobacco smoking and alcohol ...
... have successfully transplanted cultured stem cells from the healthy ... people who nearly lost their sight in accidents.Sustaining the ... who suffered from conditions such as chemical burns, allergic ... the part of the eye called limbus, were successfully ...
... exposed mainly to sign language use their hands to ... precursor to learning a language. , Dr. Laura-Ann Petitto, ... Sciences and Education at Dartmouth College// in Hanover, New ... lets them unlock the secret of their language.Conventional wisdom ...
... shows the anti-inflammatory drug naproxen may protect people ... drug (NSAID) commonly prescribed for the management of ... the effects of naproxen versus other NSAIDs //in ... heart attacks, in older patients. The study evaluated ...
... report they have successfully used gene therapy to restore ... blindness. A team of scientists led by Jean Bennett, ... this month's Nature Genetics.Their experiment involved dogs with Leber ... affects human infants and for which there is no ...
Cached Medicine News:
(Date:7/30/2015)... YORK , July 30, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Biosensors Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... Auto Suture™ ENDO RETRACT™ ... (3) atraumatic fingers, has ... of gynecologic, general, urologic, ... for temporary retraction of ...
... The Auto Suture™ ENDO PADDLE RETRACT™ ... variety of gynecologic, general, urologic,thoracic, colorectal and ... e.g., the bowel, stomach, or liver. , ... of a paddle retractor at the distal ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
Medicine Products: